Autoimmune Sample Pretreatment for Reliable Bioassays
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Biological samples from autoimmune disease subjects, particularly those with rheumatoid arthritis or systemic lupus erythematosus, contain substances that interfere with the performance of cell-based bioassays, such as neutralizing antibody assays, leading to unreliable results.
Innovation Solution
A method involving delipidation, immunoglobulin affinity purification, concentration of purified immunoglobulins, and subsequent subjecting them to a cell-based biological activity assay to remove interfering substances and enhance assay reliability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If biological samples from autoimmune disease subjects are used directly in cell-based bioassays, then the assay can be performed with minimal processing, but the results are unreliable due to interference from substances in the sample
Solution Approach 1:
The sample processing is divided into distinct sequential steps: delipidation to remove lipids, affinity purification to isolate immunoglobulins, and concentration to enrich the purified immunoglobulins. This segmentation allows each step to address specific interference sources systematically, improving assay reliability while making the complex process manageable through modular operations
Solution Approach 2:
The method performs preliminary purification and concentration of immunoglobulins before conducting the cell-based bioassay. By removing interfering substances (lipids and non-immunoglobulin proteins) in advance, the assay is protected from interference, ensuring reliable results without requiring complex interventions during the actual assay execution
2Measurement precision
If interfering substances are removed through comprehensive purification, then assay accuracy improves, but the processing time and procedural steps increase
Solution Approach 1:
The method employs affinity purification which exploits the specific binding parameter between immunoglobulins and affinity resin to selectively isolate the target molecules. This parameter-based separation achieves high purity in a single step, significantly reducing processing time compared to multiple sequential purification steps while ensuring accurate assay results by removing interfering substances
3Measurement precision
If immunoglobulins are purified and concentrated, then the signal-to-noise ratio in the assay improves, but the number of processing steps increases
Solution Approach 1:
The method combines affinity purification and concentration into an integrated workflow where purified immunoglobulins are directly concentrated in the same processing system. This merging of operations achieves both high purity (improving signal-to-noise ratio) and high concentration in a unified process, reducing the number of separate processing steps compared to performing purification and concentration as entirely separate operations
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method effectively removes interfering substances, allowing for more reliable results in cell-based bioassays by purifying and concentrating immunoglobulins from autoimmune disease subjects, thereby improving the accuracy of biological activity assessments.
Implementation Method 1
incubating the delipidated sample with an affinity purification medium under conditions that allow binding of immunoglobulins to the affinity purification medium
Implementation Method 2
subjecting the concentrated immunoglobulins to a cell-based biological activity assay
Data Source
Figure 1A
Figure 1B
Figure 2
AI summary
The present application describes a method for pretreating a biological sample from an autoimmune disease subject in order to avoid interference, especially where the sample is to be subjected to a cell-based biological activity assay, such as a neutralizing antibody assay.